Blood Sugar News and Research

RSS

Blood sugar concentration, or glucose level, refers to the amount of glucose present in the blood of a human or animal. Normally, in mammals the blood glucose level is maintained at a reference range between about 3.6 and 5.8 mM (mmol/l). It is tightly regulated as a part of metabolic homeostasis.

Patients with early AD also have undiagnosed pre-diabetes, says Georgetown neurologist

When Georgetown University neurologist R. Scott Turner, MD, PhD, began enrolling people with mild to moderate Alzheimer's disease into a nationwide study last year, he expected to find only a handful of participants with undiagnosed glucose intolerance, as all the patients were already under a doctor's care and those with known diabetes were excluded.

15 Jul 2013

Viewpoints: 'Implosion' of the ACA; Administration 'spin machine'; Republicans on 'search-and-destroy' mission

July 3 was the quiet afternoon that a deputy assistant Treasury secretary for tax policy announced in a blog post that the Affordable Care Act's employer mandate would be delayed one year. Something about the "complexity of the requirements." ... Even if you are a liberal and support the goals of the Affordable Care Act, there has to be an emerging sense that maybe the law's theorists missed a signal from life outside the castle walls. While they troweled brick after brick into a 2,000-page law, the rest of the world was reshaping itself into smaller, more nimble units whose defining metaphor is the 140-character Twitter message (Daniel Henninger, 7/10).

12 Jul 2013

Risk-factor screening of high-risk children may delay or prevent chronic health conditions later in life

Mexican American children are experiencing substantial burdens of obesity, pre-diabetes, and other health problems which historically would have been expected to develop much later in life. The findings of a new study by Texas Biomed scientists in San Antonio argue for early screening and intervention to delay or avoid chronic health problems as these children age.

12 Jul 2013

Comprehensive analysis of disease burden in US

In nearly every major cause of premature death - from ischemic heart disease to diabetes to interpersonal violence - the United States trails its economic peers, according to new research from a global collaborative of scientists led by the Institute for Health Metrics and Evaluation at the University of Washington.

12 Jul 2013

Weight loss interventions deliver via conference calls by primary care provider staff are effective

Weight loss interventions delivered via conference calls by primary care provider staff are effective. An intensive lifestyle intervention, proven to help people lose weight to prevent diabetes, also works in primary care when delivered over the telephone to obese patients with metabolic syndrome. Group telephone sessions appear to be particularly effective for greater weight loss, according to a new study by Drs. Paula Trief and Ruth Weinstock from SUNY Upstate Medical University in Syracuse, New York, and colleagues.

10 Jul 2013

TGA of Australia approves Vertex Pharmaceuticals' KALYDECO for cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced that the Therapeutic Goods Administration of Australia has approved KALYDECO (ivacaftor) for people with cystic fibrosis ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator gene.

10 Jul 2013

Acorda Therapeutics acquires two neuropathic pain management assets from NeurogesX

Acorda Therapeutics, Inc. today announced that it has acquired two neuropathic pain management assets from NeurogesX, Inc. Qutenza is approved by the U.S. Food and Drug Administration for the management of neuropathic pain associated with postherpetic neuralgia.

9 Jul 2013

Individualised care can make huge difference in older patients with type 2 diabetes

More than a quarter of over 70s with type 2 diabetes could benefit simply from improving communication and education in the clinic, new research has revealed. A study led by the University of Exeter Medical School and published in The Lancet found that 27 percent achieved better glycaemic control through individualised care alone.

9 Jul 2013

Study describes how human mammary gland becomes highly sensitive to insulin during lactation

Why do so many mothers have difficulty making enough milk to breastfeed? A new study by scientists at Cincinnati Children's Hospital Medical Center and the University of California Davis adds to their previous research implicating insulin's role in lactation success.

6 Jul 2013

Salsalate lowers blood glucose and improves glycemic control in T2D, say scientists

Joslin scientists report that salsalate, a drug used to treat arthritis, lowers blood glucose and improves glycemic control in type 2 diabetes. These findings, which were published today by the Annals of Internal Medicine, provide additional evidence that salsalate may be an effective drug to treat type 2 diabetes.

3 Jul 2013

Curing type 1 diabetes: an interview with Dr. Habib Zaghouani, MU School of Medicine

Type 1 diabetes is an attack by the immune system of the islet of Langerhans within the pancreas. Basically, the islet of Langerhans harbor beta cells, which produce insulin and when the islets are attacked, the beta cells destruct and there is no more insulin. When the insulin level goes low, blood glucose levels go high and that creates a problem.

28 Jun 2013

UK, Canada experience huge decline in diabetes mortality rates since mid-1990

Both the UK and Canada have experienced huge falls in diabetes-related mortality since the mid-1990s, with the result that the gap in mortality risk between those with and without diabetes has narrowed substantially.

27 Jun 2013

UCI researchers receive $2.27M to develop innovative methods of treating Type 1 diabetes.

Two UC Irvine research groups have received $2.27 million from the JDRF to develop innovative methods of treating and possibly curing Type 1 diabetes.

27 Jun 2013

Eisai submits BELVIQ NDS with Health Canada

Arena Pharmaceuticals, Inc. announced today that Eisai Limited (based in Mississauga, Ontario), a subsidiary of Eisai Inc., has submitted a New Drug Submission for BELVIQ (lorcaserin HCl) with Health Canada.

26 Jun 2013

Promising approach to reduce risk of hypoglycemia in diabetes shows positive results

People with type 1 diabetes who rely on insulin injections to control their blood sugar levels are at risk for life-threatening hypoglycemic events in which their blood glucose levels drop dangerously low.

25 Jun 2013

State highlights: Calif. eyes health care for immigrants; New scrutiny for N.Y. home health firms; Examining Ore. insurers' choice on smokers

When Congress passed President Obama's health care overhaul, a critical compromise provision was that immigrants living in the United States illegally would not be allowed access to publicly subsidized health insurance.

25 Jun 2013

Weight loss does not reduce heart disease risks among Type 2 diabetes patients: Study

A landmark study investigating the long-term effects of weight loss on the risks of cardiovascular disease among patients with Type 2 diabetes has now concluded, with significant results to be published today in the New England Journal of Medicine.

25 Jun 2013

Patients with type2 diabetes, renal impairment have less hypoglycemia with JANUVIA compared to sulfonylurea

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc pooled analysis showing patients with type 2 diabetes and mild renal impairment treated with JANUVIA- (sitagliptin) 100 mg once-daily achieved similar blood sugar reductions as those treated with the sulfonylureas glipizide or glimepiride, with significantly fewer events of hypoglycemia (low blood sugar), and with weight loss instead of weight gain.

24 Jun 2013

Sanofi reports Phase 3 study of insulin U300 shows better blood sugar control than Lantus

Sanofi announced today that the first Phase 3 study results for its investigational new insulin U300 showed equivalent blood sugar control with fewer night-time low blood sugar events compared to Lantus.

24 Jun 2013

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a new study in which linagliptin demonstrated statistically significant reductions in blood glucose levels (HbA1c) after 12 weeks (the study's primary endpoint) in adults with type 2 diabetes (T2D) with moderate to severe renal impairment, compared with placebo. Most patients had T2D for more than ten years (76 percent) and were on insulin (86 percent).

24 Jun 2013

Blood Sugar News and Research

Further Reading

Patients with early AD also have undiagnosed pre-diabetes, says Georgetown neurologist

Viewpoints: 'Implosion' of the ACA; Administration 'spin machine'; Republicans on 'search-and-destroy' mission

Risk-factor screening of high-risk children may delay or prevent chronic health conditions later in life

Comprehensive analysis of disease burden in US

Weight loss interventions deliver via conference calls by primary care provider staff are effective

TGA of Australia approves Vertex Pharmaceuticals' KALYDECO for cystic fibrosis

Acorda Therapeutics acquires two neuropathic pain management assets from NeurogesX

Individualised care can make huge difference in older patients with type 2 diabetes

Study describes how human mammary gland becomes highly sensitive to insulin during lactation

Salsalate lowers blood glucose and improves glycemic control in T2D, say scientists

Curing type 1 diabetes: an interview with Dr. Habib Zaghouani, MU School of Medicine

UK, Canada experience huge decline in diabetes mortality rates since mid-1990

UCI researchers receive $2.27M to develop innovative methods of treating Type 1 diabetes.

Eisai submits BELVIQ NDS with Health Canada

Promising approach to reduce risk of hypoglycemia in diabetes shows positive results

State highlights: Calif. eyes health care for immigrants; New scrutiny for N.Y. home health firms; Examining Ore. insurers' choice on smokers

Weight loss does not reduce heart disease risks among Type 2 diabetes patients: Study

Patients with type2 diabetes, renal impairment have less hypoglycemia with JANUVIA compared to sulfonylurea

Sanofi reports Phase 3 study of insulin U300 shows better blood sugar control than Lantus

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News